Case Study: GLP-1 agonists in type 2 diabetes´┐╝

Rybelsus (semaglutide) is a daily oral GLP-1 agonist for Type 2 diabetes that has A1C lowering as strong as injected Victoza (liraglutide) 1.8mg and somewhat better weight loss (-4.4kg versus -3.1kg to week 26), with similar gastrointestinal side effects. For proper oral absorption, it must be taken at least 30 minutes before the first food, beverage, or other oral medications of the day.

Rybelsus (semaglutide) is a daily oral GLP-1 agonist for Type 2 diabetes that has A1C lowering as strong as injected Victoza (liraglutide) 1.8mg and somewhat better weight loss (-4.4kg versus -3.1kg to week 26), with similar gastrointestinal side effects. For proper oral absorption, it must be taken at least 30 minutes before the first food, beverage, or other oral medications of the day.

Cardiology Options for Patient With History of Heart Disease

A 55-year-old female presents with an extended history of heart disease. Using thallim scintigraphy, a large and nonreversible anterior septal segment defect was found. Because the myocardium was determined to be nonviable, the woman was to be evaluated for a cardiac transplant.

A 55-year-old female presents with an extended history of heart disease. Using thallim scintigraphy, a large and nonreversible anterior septal segment defect was found. Because the myocardium was determined to be nonviable, the woman was to be evaluated for a cardiac transplant.

Uncontrolled Diabetes

A 51-year-old male patient with type 2 diabetes (T2DM) takes metformin 1000 mg twice daily, glipizide 10mg twice daily, and NPH insulin (35 units in the morning and 10 units in the evening). Despite all the meds, the patient still has frequent hyperglycemic reactions.

A 51-year-old male patient with type 2 diabetes (T2DM) takes metformin 1000 mg twice daily, glipizide 10mg twice daily, and NPH insulin (35 units in the morning and 10 units in the evening). Despite all the meds, the patient still has frequent hyperglycemic reactions.